Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 396

1.

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.

Clin Cancer Res. 2004 Aug 1;10(15):4939-43.

2.

Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.

Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.

Lung Cancer. 2004 Jun;44(3):311-6.

PMID:
15140544
3.

[Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].

Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Zhang XR, Sun Y, Xu BH, Lin DX.

Ai Zheng. 2005 Dec;24(12):1510-3. Chinese.

PMID:
16351803
4.

[Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy].

Wang J, Zhang Q, Zhang H, Wang Q, Yang X, Gu Y, Zhang S.

Zhongguo Fei Ai Za Zhi. 2010 Apr;13(4):337-41. doi: 10.3779/j.issn.1009-3419.2010.04.13. Chinese.

5.

Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.

Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg D, Liu G, Christiani DC.

Clin Cancer Res. 2005 Feb 15;11(4):1534-8.

6.

DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.

Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D.

Clin Lung Cancer. 2009 Mar;10(2):118-23. doi: 10.3816/CLC.2009.n.015.

PMID:
19362955
7.

Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.

Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.

Am J Clin Oncol. 2010 Oct;33(5):489-94. doi: 10.1097/COC.0b013e3181b9cedc.

PMID:
20351547
8.

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.

Jpn J Clin Oncol. 2010 Oct;40(10):954-60. doi: 10.1093/jjco/hyq071. Epub 2010 May 12.

PMID:
20462983
10.

ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ.

Clin Adv Hematol Oncol. 2003 Mar;1(3):162-6.

PMID:
16224397
11.

Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.

Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, Sun T, Zhao D, Yang M, Liu J, Xu B, Lin D.

Clin Cancer Res. 2008 May 1;14(9):2878-86. doi: 10.1158/1078-0432.CCR-07-1612.

12.

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

Vilmar A, Sørensen JB.

Lung Cancer. 2009 May;64(2):131-9. doi: 10.1016/j.lungcan.2008.08.006. Epub 2008 Sep 19. Review.

PMID:
18804893
13.

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J.

Cancer Invest. 2010 Dec;28(10):1078-83. doi: 10.3109/07357901003735659. Epub 2010 May 26.

PMID:
20504223
14.

Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer.

Okuda K, Sasaki H, Hikosaka Y, Kawano O, Yukiue H, Yano M, Fujii Y.

J Surg Res. 2011 Jun 15;168(2):206-12. doi: 10.1016/j.jss.2009.09.006. Epub 2009 Sep 26.

PMID:
20070981
15.

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC.

J Clin Oncol. 2004 Jul 1;22(13):2594-601. Epub 2004 Jun 1.

PMID:
15173214
16.

Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.

Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A, Aizawa H.

Cancer Sci. 2007 Sep;98(9):1336-43. Epub 2007 Jul 19.

17.

ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.

Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.

J Clin Oncol. 2007 Nov 20;25(33):5172-9.

PMID:
18024864
18.

Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer.

Zhou W, Liu G, Park S, Wang Z, Wain JC, Lynch TJ, Su L, Christiani DC.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):491-6.

19.

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.

Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.

Lung Cancer. 2009 Aug;65(2):230-6. doi: 10.1016/j.lungcan.2008.11.014. Epub 2009 Jan 20.

PMID:
19157633
20.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

PMID:
18977553

Supplemental Content

Support Center